Interindividual variation is important in the response to metformin as the first-line therapy for type-2 diabetes mellitus (T2DM). Considering that OCT1 and MATE1 transporters determine the metformin pharmacokinetics, this study aimed to investigate the influence of SLC22A1 and SLC47A1 variants on the steady-state pharmacokinetics of metformin and the glycemic response. This research used the prospective-cohort study design for 81 patients with T2DM who received 500 mg metformin twice a day from six primary healthcare centers. SLC22A1 rs628031 A>G (Met408Val) and Met420del genetic variants in OCT1 as well as SLC47A1 rs2289669 G>A genetic variant in MATE1 were examined through the PCR-RFLP method. The bioanalysis of plasma metformin was performed in the validated reversed-phase HPLC-UV detector. The metformin steady-state concentration was measured for the trough concentration (Cssmin) and peak concentration (Cssmax). The pharmacodynamic parameters of metformin use were the fasting blood glucose (FBG) and glycated albumin (GA). Only SLC22A1 Met420del alongside estimated-glomerular filtration rate (eGFR) affected both Cssmax and Cssmin with an extremely weak correlation. Meanwhile, SLC47A1 rs2289669 and FBG were correlated. This study also found that there was no correlation between the three SNPs studied and GA, so only eGFR and Cssmax influenced GA. The average Cssmax in patients with the G allele of SLC22A1 Met408Val, reaching 1.35-fold higher than those with the A allele, requires further studies with regard to metformin safe dose in order to avoid exceeding the recommended therapeutic range.
1 January 2018 in Research Journal of Pharmacy and Technology
Widely used as the mainstay therapy of type-2 diabetes patients, the plasma level of metformin should remain within therapeutic range (0.75–5.00 μg/mL) to gain optimal effectiveness without lactic acidosis. An HPLC-UV method has been developed and validated for the determination of metformin in spiked-human plasma according to the FDA Guidance of Bioanalysis. Optimum determination was achieved by using a mixture of 55% buffer pH 5.2 (6 mM potassium dihydrogen phosphate-6 mM sodium dodecyl sulphate) and 45% acetonitrile with Sunfire® C-18 column, 150x4.6mmx5μm from Waters, and SM7 injector with UV detector at 233 nm of wavelength. The analyte was extracted from plasma using 10% trichloroacetic acid. The assay was linear over the therapeutic steady-state concentration range of 0.50–7.00 μg/mL for metformin HCl with correlation coefficient 0.9999. The limit of detection was 0.14 μg/mL. The obtained results from accuracy, precision, and selectivity tests complied well with the generally accepted criteria for bioanalytical assay. The validated method could be used for determining metformin in human plasma and monitoring the metformin therapy in a clinical setting for dose adjustment, particularly for the elderly and patients with renal impairment as well as for measuring metformin accumulation.
1 June 2018 in Journal of Clinical & Translational Endocrinology
This prospective study aimed to analyze metformin steady-state concentration in repeated constant dosage and the influencing patient-factors as well as to correlate them with glycemic control. The validated HPLC-UV method was used to examine metformin steady-state concentration, while FBG and glycated albumin were used as the parameters of glycemic control during metformin administration. A total of 82 type-2 diabetes patients were involved with 32.1% of them having metformin Cssmin and 84.1% having Cssmax of metformin within the recommended therapeutic range. One patient had metformin Css that exceeded minimum toxic concentration despite his normal renal function and administered therapeutic dosage of metformin. Higher Cssmax was found in patients with metformin monotherapy, while patients with longer duration of metformin use had significantly higher Cssmin. Along with initial hyperglycemia and eGFR, metformin Cssmin became the only parameter that influenced FBG level (P < 0.05). Duration of previous metformin use should be considered in the strategy of optimizing metformin dosage. The type-2 diabetes patients with obesity are more suggested to take shorter interval of metformin administration (or possibly with sustained-release formulation) to keep Cssmin within the therapeutic range.
21 February 2018 in Current Pharmacogenomics and Personalized Medicine
Background: Single Nucleotide Polymorphisms (SNPs) in metformin transporter genes play an important role as the cause of inter-individual variability in metformin response. The SLC22A1 as an Organic Cation Transporter (OCT)1 coding gene is responsible for the metformin influx to hepatocytes, while the efflux to bile and excretion through the kidney are mainly facilitated by Multidrug and Toxin Extrusion (MATE)1 transporter coded by the SLC47A1. Objective: This study aimed to determine the distribution of allele frequencies in rs628031 A>G (M408V) OCT1 and rs2289669 G>A MATE1 among the Javanese population as the largest ethnic group in Indonesia with type-2 diabetes mellitus (T2DM). Method: The study involved 86 adult patients with T2DM. The genotyping to analyze the target SNPs used the PCR-RFLP method. Results: The frequencies of G allele of rs628031 in SLC22A1 and A allele of rs2289669 in SLC47A1 were 60.47% and 61.05% respectively. There was no significant correlation of the allele frequencies of both SLC22A1 rs628031 and SLC22A1 rs628031 between female and male patients (P>0.05). Conclusion: The allele frequency of SLC22A1 gene rs628031 in Javanese-Indonesian population was almost the same as those found in Afro-American population as well as in other Asian populations. Similar results were obtained when the A allele frequency of SLC47A1 rs2289669 was compared to those in Chinese population. Further studies are recommended to examine the correlation between these polymorphisms and the variability of pharmacokinetic profiles as well as glycemic response to metformin and its adverse reactions.
14 February 2019 in Open Access Macedonian Journal of Medical Sciences
BACKGROUND: Genetic variation in the genes that encode metformin transporters has been proven to cause pharmacokinetic variability and various glycemic response to metformin. Organic Cation Transporter (OCT) 1 protein encoded by the SLC22A1 gene is primarily responsible for the process of metformin influx to the hepatocytes as the target of antihyperglycemic action as well as metformin elimination through the renal. This study aimed to determine the allele frequency distribution of the SLC22A1 Met420del gene in OCT1 among the Javanese population, the largest ethnic group in Indonesia with T2DM. METHODS: The research involved 100 adult patients from 9 healthcare facilities in Yogyakarta Province. The PCR-RFLP method was employed as a genotype analysis to detect polymorphism using 5'-AGGTTCACGGACTCTGTGCT-3' forward primer and 5'-AAGCTGGAGTGTGCGATCT-3' reverse primer. RESULTS: No AA variant (wild type) type was found in the SLC22A1 Met420del gene, and only 4% of the subjects had Aa heterozygote type. The allele frequencies of A and a were 2.0% and 98.0% in all subjects, respectively. CONCLUSION: The allele frequencies in the Javanese-Indonesian population were almost the same as those in the studies involving Japanese, Chinese-Han, and Asian-American populations. This study recommends further research on the correlation between the influence of methionine deletion at codon 420 on the variability of pharmacokinetic profiles and the glycemic response to metformin as well as the incidence of gastrointestinal intolerance due to metformin administration.
2 January 2020 in Open Access Macedonian Journal of Medical Sciences
BACKGROUND: Genetic variations in ABCB1 gene that encodes P-glycoprotein, the main transporter in the efflux of carbamazepine (CBZ) from the brain cells, can lead to pharmacodynamic and pharmacokinetic variability. Polymorphism of C3435T is widely known to cause protein overexpression that contributes to an increased risk of CBZ resistance. AIM: This study determined the allele frequency distribution of ABCB1 C3435T gene in healthy subjects of the Javanese population as a major ethnic group in Indonesia. METHODS: This cross-sectional study involved 100 healthy volunteers who fulfilled the inclusion criteria. The genotype analysis to detect polymorphism in the targets employed the polymerase chain reaction-restriction fragment length polymorphism method with 5’-TGCTGGTCCTGAAGTTGATCTGTGAAC-3’ as the forward primer and 5’-ACATTAGGCAGTGACTCGATGAAGGCA-3’ as the reverse primer. RESULTS: The frequency of subjects with C allele in ABCB1 C3435T gene reached 53%, higher than that with T allele. CONCLUSION: This finding was nearly the same as that in studies of the populations in China, Turkey, and four countries in the South European continent. It is recommended to conduct further research on the correlation between C3435T polymorphism and CBZ dose variability to provide a comprehensive approach to epilepsy management in patients receiving CBZ.